FY24 consensus $761.46M. Cuts FY24 product sales view to $175M-$225M from $275M-$375M. Raises FY24 Licensing, Royalties and Other Revenue view to $475M from $425M.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Options Volatility and Implied Earnings Moves Today, November 12, 2024
- Unusually active option classes on open November 11th
- Novavax: FDA removes clinical hold on Covid-19/flu combo trial
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- Novavax Settles Vaccine Supply Agreement Dispute